chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 75.0
Sex: F
Vaccine: COVID19
Symptoms: Nausea, Sleep deficit, Vaccination site pain
Clinical narrative: Nausea; Headache; Chills; Dizziness; Feeling unwell; Tiredness; Pain at injection site; Could not sleep the night of thesecond vaccine.; This is a spontaneous report from a contactable consumer, the patient. A 75-year-old-female non-pregnant patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6205), via an unspecified route of administration in the left arm on 06Mar2021 at 01:45 for COVID-19 immunisation. Medical history included penicillin allergy. Concomitant medications included DYAZIDE, vitamin C (MANUFACTURER UNKNOWN), vitamin D (MANUFACTURER UNKNOWN), fish Oil (MANUFACTURER UNKNOWN), biotin (MANUFACTURER UNKNOWN) and flavonoid (MANUFACTURER UNKNOWN); all were taken for unknown indication from an unknown date. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EL9266), via an unspecified route of administration in the left arm on 13Feb2021 at 01:45 for COVID-19 immunisation. Prior to vaccination, the patient was not diagnosed with COVID-19 and since the vaccination, the patient was tested for COVID-19. The patient has not received any other vaccines within 4 weeks prior to the COVID vaccine. On 06Mar2021, the patient could not sleep the night of the second vaccine and experienced nausea, headache, chills, dizziness, feeling unwell, tiredness and pain at injection site at night. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. No treatment was received for the adverse events. The clinical outcome of the events could not sleep the night of the second vaccine, nausea, headache, chills, dizziness, feeling unwell, tiredness and pain at injection site was recovered (all for a couple of days) at the time of reporting.   No follow-up attempts are needed. No further information is expected.
Age: 36.0
Sex: M
Vaccine: COVID19
Symptoms: Body temperature, Fatigue, Malaise, Pyrexia
Clinical narrative: Fatigue; malaise; Fever of 99.7; This is a spontaneous report received from a contactable consumer. A 36-year-old male patient received an unspecified dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN) via an unspecified route of administration in right arm on 22Mar2021 at 10:30, (at the age of 36-years) as single dose, for COVID-19 immunisation. Medical history included hypertension. The patient did not have any allergies to food, medications, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested positive for COVID-19. Concomitant medication included lisinopril 40 mg (MANUFACTURER UNKNOWN), taken from an unknown date, and taken for an unknown indication. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 22Mar2021, the patient experienced fatigue and malaise within 5 minutes of injection that persisted all day. On 22Mar2021 the patient experienced fever of 99.7-degree Fahrenheit 5-6 hours following vaccination. The adverse events had not resulted in doctor or other healthcare professional office/clinic visit/ emergency visit/ department or urgent care. The patient's physical examination included body temperature on 22Mar2021 that was found to be 99.7-degree Fahrenheit. The patient did not receive any treatment for the events. The clinical outcome of the events fatigue, malaise and fever of 99.7 degree Fahrenheit was not recovered at the time of this report. Information about lot number cannot be obtained. No further information expected.
Age: 66.0
Sex: F
Vaccine: COVID19
Symptoms: Body temperature, Chills, Fatigue, Headache, Lymphadenopathy
Clinical narrative: Swelling of injection site with expanding deep red hive-like rash; deep red hive-like rash; fever; Chills; Slight headache; Swollen lymph glands in armpit; Fatigue; General malaise; Arm rash is troublesome; This is a spontaneous report from a contactable consumer, the patient. A 66-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: Unknown) via an unspecified route on 20Mar2021 at 1330 (at the age of 66-years-old) as a single dose for COVID-19 immunisation. The patient medical history included irritant induced asthma, latex allergy, myalgic encephalomyelitis (chronic fatigue syndrome), hypothyroidism and alpha gal allergy. Concomitant medications included ambien (MANUFACTURER UNKNOWN), levothyroxine (MANUFACTURER UNKNOWN), liothyronine (MANUFACTURER UNKNOWN) and b12 tablets (MANUFACTURER UNKNOWN), all taken for unknown indications from unknown dates. The patient was allergic to latex, sulfa medicines and beef. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: Unknown) via an unspecified route on 27Feb2021 at 1730 as a single dose for COVID-19 immunisation. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested positive for COVID-19. It was reported that the patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. On 21Mar2021, the patient experienced swelling of injection site with expanding deep red hive-like rash hot to touch, grew 2 inches in size in 24 hours and getting bigger, fever of 101, chills, slight headache, swollen lymph glands in armpit, fatigue, general malaise and arm rash. It was reported that the patient took tylenol (MANUFACTURER UNKNOWN) for fever. No other treatment was taken for the events experienced. The clinical outcome of the events swelling of injection site, expanding deep red hive-like rash hot to touch, fever of 101, chills, slight headache, swollen lymph glands in armpit, fatigue, general malaise and arm rash was not recovered at the time of this report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 66.0
Sex: F
Vaccine: COVID19
Symptoms: Malaise, Pyrexia, Rash, Urticaria, Vaccination site swelling
Clinical narrative: Swelling of injection site with expanding deep red hive-like rash; deep red hive-like rash; fever; Chills; Slight headache; Swollen lymph glands in armpit; Fatigue; General malaise; Arm rash is troublesome; This is a spontaneous report from a contactable consumer, the patient. A 66-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: Unknown) via an unspecified route on 20Mar2021 at 1330 (at the age of 66-years-old) as a single dose for COVID-19 immunisation. The patient medical history included irritant induced asthma, latex allergy, myalgic encephalomyelitis (chronic fatigue syndrome), hypothyroidism and alpha gal allergy. Concomitant medications included ambien (MANUFACTURER UNKNOWN), levothyroxine (MANUFACTURER UNKNOWN), liothyronine (MANUFACTURER UNKNOWN) and b12 tablets (MANUFACTURER UNKNOWN), all taken for unknown indications from unknown dates. The patient was allergic to latex, sulfa medicines and beef. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: Unknown) via an unspecified route on 27Feb2021 at 1730 as a single dose for COVID-19 immunisation. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested positive for COVID-19. It was reported that the patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. On 21Mar2021, the patient experienced swelling of injection site with expanding deep red hive-like rash hot to touch, grew 2 inches in size in 24 hours and getting bigger, fever of 101, chills, slight headache, swollen lymph glands in armpit, fatigue, general malaise and arm rash. It was reported that the patient took tylenol (MANUFACTURER UNKNOWN) for fever. No other treatment was taken for the events experienced. The clinical outcome of the events swelling of injection site, expanding deep red hive-like rash hot to touch, fever of 101, chills, slight headache, swollen lymph glands in armpit, fatigue, general malaise and arm rash was not recovered at the time of this report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 70.0
Sex: F
Vaccine: COVID19
Symptoms: Haemoptysis
Clinical narrative: Coughing up blood; This is a spontaneous report from a contactable consumer, the patient. A 70-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EP7534), via an unspecified route of administration in the right arm on 20Mar2021 at 13:00 (at the age of 70-years-old), as a single dose for COVID-19 immunisation. Medical history included Hepatitis C, emphysema and penicillin allergy. Concomitant medications included calcium (MANUFACTURER UNKNOWN), vitamin D3 (MANUFACTURER UNKNOWN) and vitamin b12 (MANUFACTURER UNKNOWN); all for unknown indication from unknown date. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6202), via an unspecified route of administration in the left arm on 27Feb2021 (at the age of 69-years-old), as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within 4 weeks prior to the COVID-19 vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 22Mar2021 at 06:00, the patient was coughing up blood when she woke up. The event resulted in doctor or other healthcare professional office/clinic visit. The patient did not receive any treatment for the event. The clinical outcome of the event coughing up blood was recovered on 22Mar2021.  No follow-up attempts are needed. No further information is expected.
Age: 63.0
Sex: F
Vaccine: COVID19
Symptoms: Muscle spasms
Clinical narrative: Severe back spasm; This is a spontaneous report from a contactable consumer, the patient. A 63-Year-old non pregnant female patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; lot number: ER8727), via unspecified route of administration in right arm on 19Mar2021 at 02:00 pm (at the age of 63-years-old) as a single dose for COVID-19 immunisation. Medical history included S/P bilateral mastectomy, H/O bilateral breast cancer, hypertension, GERD, eczema, anxiety/depression, recurrent HSV, H/O HPV 18 infection and back spasms. Concomitant medications include pantoprazole (MANUFACTURER UNKNOWN) at a dose of 40 mg and olmesartan medoxomil (MANUFACTURER UNKNOWN) at a dose of 40 mg on an unknown date for unknown indication. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient has not had symptoms associated with COVID-19. Patient had not tested positive for COVID-19 since having the vaccine. The patient was allergic to ceftriaxone, ACE inhibitors, zoloft, craw fish, environmental elements like dust mites, pet hair and pollen. The patient had H/O back spasms. After the Pfizer COVID-19 vaccine, on 20Mar2021, at 09:00 am, the patient suffered from severe back spasm. Severe back spasm occurred as soon as the patient stood up, real painful, pain rated 10. The patient had to immediately go back to bed to relieve the pain, because the pain was debilitating. The patient did not receive any treatment for the event. The clinical outcome of the event severe back spasm was recovered on 21Mar2021. No follow-up attempts are needed. No further information is expected.
Age: 67.0
Sex: M
Vaccine: COVID19
Symptoms: Fatigue, Nausea, Pain, Vertigo
Clinical narrative: Severe vertigo; nausea; Fatigue; body aches; This is a spontaneous report received from a contactable consumer, the patient. A 67-year-old male patient received his second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number EN6204) via an unspecified route of administration in the left arm on 08Mar2021 at 13:45 as a single dose for COVID-19 immunisation. Relevant medical history was not reported. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Concomitant medications received within 2 weeks of vaccination included acetaminophen (MANUFACTURER UNKNOWN) 30 hours after shot for unspecified indication and B-12 (MANUFACTURER UNKNOWN) for unspecified indication from an unknown date. The patient previously took the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number EN6200) via an unspecified route of administration in left arm on 15Feb2021 at 14:00 as a single dose for COVID-19 immunisation. The patient took terbinafine (MANUFACTURER UNKNOWN) in the past and experienced allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested positive for COVID-19. On 09Mar2021 at 05:00, the patient experienced fatigue and body aches which resolved in one day. On 10Mar2021, the patient experienced severe vertigo and some nausea upon awakening. Gradually and slowly resolved during the day, but effect continues to linger even after 15 days. No therapeutic measures were taken as a result of the reported events. Adverse events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events severe vertigo and nausea was resolving while the outcome of fatigue and body ache was resolved on 10Mar2021. No follow-up attempts are needed. No further information is expected.
Age: 48.0
Sex: F
Vaccine: COVID19
Symptoms: Flushing, Hypoaesthesia, Pallor, Paraesthesia, Raynaud's phenomenon
Clinical narrative: Raynaud's like symptoms; Numbness of finger tips; paleness of fingertips; flushing; tingling; This is a spontaneous report from a contactable nurse, the patient. A 48-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EL3248), via intramuscular route in the left arm on 09Jan2021 at 14:00 (at the age of 48-years-old) as a single dose for COVID-19 immunisation. Medical history included lymphocytic colitis. The patient previously received first dose of BNT162b2 (PFIZER BIONTECH COVID-19 mRNA VACCINE, Lot number: EK5730) in the left arm on 19Dec2020 at 12:00 (at the age of 48-years-old) as a single dose for Covid-19 immunisation. Past drug history included allergic to TORADOL. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. Concomitant medications included PRISTIQ and budesonide (MANUFACTURER UNKNOWN) for unknown indications. On 01Feb2021, the patient experienced raynaud's like symptoms, numbness and paleness of fingertips, followed by flushing and tingling. The events resulted in doctor or other healthcare professional office/clinic visit. The patient did not receive treatment for the reported events. The clinical outcome of the events raynaud's like symptoms, numbness and paleness of fingertips, followed by flushing and tingling was not resolved. No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 65.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Headache, Pain, Pain in extremity, Vaccination site pain
Clinical narrative: Sore injection site; Sore arm; Headache; Chills; Acheness; This is a spontaneous report from a contactable consumer, the patient. A 65-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, lot number: EN6202) via an unspecified route of administration in the left arm on 21Mar2021 at 13:45 (at the age of 65-years-old) as a single dose for COVID-19 immunisation. The patient had no medical history. The patient did not receive any concomitant medications within two weeks of vaccination. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, lot number: paaa156051) via an unspecified route of administration on 28Feb2021 at 15:30 (at the age of 65-years-old) as a single dose for COVID-19 immunisation. The patient had no known allergies to medications, food or other products. The patient had not receive any other vaccines within four weeks prior to the COVID vaccine. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 21Mar2021 at 16:00, the patient experienced soreness in injection site, headache, chills, sore arm and acheness. The patient did not receive any treatment for the events. The clinical outcome of vaccination site pain, pain in arm, headache, chills and ache was recovered on unknown date in Mar2021. No follow-up attempts are needed. No further information is expected.
Age: 49.0
Sex: F
Vaccine: COVID19
Symptoms: Pruritus
Clinical narrative: itchy skin especially in cheeks; This is a spontaneous report from a non-contactable consumer, the patient. A 49-years-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: EL9267) via an unspecified route of administration in left arm on 22Mar2021 at 07:45 (at the age of 49-years) as a single dose for COVID-19 immunisation. The medical history of the patient included diabetes mellitus type-2 and the patient was allergic to erythromycin. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient took unspecified medications within 2 weeks of vaccination. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient was not tested for COVID-19. The patient experienced itchy skin especially in cheeks on 22Mar2021 at 07:45. The patient did not receive any treatment for the reported event. Event didn't result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the event was unknown.   No follow-up attempts are needed. No further information is expected.
Age: 59.0
Sex: F
Vaccine: COVID19
Symptoms: Hypoaesthesia, Oropharyngeal pain, Pain in extremity, Paraesthesia
Clinical narrative: Arm was barely sore; very slight sore throat; Both hands are very numb; pins and needles; This is a spontaneous report from a contactable consumer, the patient. A 59-year-old non-pregnant female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: Ep7534), via an unspecified route of administration in the left arm on 19Mar2021 at 16:00 (at the age of 59-years-old), as a single dose for COVID-19 immunisation. Medical history (reported as she was super healthy). The patient previously received cortisone for an unknown indication and experienced allergy. The patient did not receive any other vaccines within 4 weeks prior to the COVID-19 vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not take any other medications within two weeks of vaccination. On 21Mar2021 at 16:00, the patient experienced barely sore arm, only a very slight sore throat and both hands were very numb with no swelling or discolor or facial droop but pins and needles. The patient did not receive treatment for the reported events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events barely sore arm, very slight sore throat, both hands very numb and pins and needles was not resolved at the time of this report. No follow-up attempts are needed. No further information is expected.
Age: 34.0
Sex: M
Vaccine: COVID19
Symptoms: Pyrexia
Clinical narrative: Fever; This is a spontaneous report from a contactable consumer, the patient. A 34-years-old male patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN), via unspecified route of administration in the left arm on 04Mar2021 at 12:45 (at the age of 34-years-old), as a single dose for COVID-19 immunisation. Medical history was not reported. The patient was allergic to Tegretol and pertussis. Prior to vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included estradiol (MANUFACTURER UNKNOWN), finasteride (MANUFACTURER UNKNOWN), (LEXAPRO), buspirone (MANUFACTURER UNKNOWN) all for unknown indications and from an unknown date. The patient did not receive any other vaccines within 4 weeks prior to the COVID-19 vaccine. Since the vaccination, the patient had not been tested for COVID-19. On 22Mar2021 at 17:30, the patient experienced fever. It was unknown whether therapeutic measures were taken for the event fever. The clinical outcome of the event fever was not recovered at the time of reporting. Information about lot number cannot be obtained.   No further information is expected.
Age: 82.0
Sex: M
Vaccine: COVID19
Symptoms: Arthralgia, Chills, Diarrhoea
Clinical narrative: Diarrhea; Joint pain; Chills; This is a spontaneous report received from a contactable consumer. A 82-year-old male patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: Unknown) via an unspecified route of administration in the right arm on 28Feb2021 at 13:00 (at the age of 82-year-old) as a single dose for COVID-19 immunisation. The patient had medical history included diabetes, high blood pressure and stroke. It was not sure if the patient had allergies to medications, food, or other products. It was not sure whether any concomitant medications was taken by the patient. Prior to the vaccination the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19 The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: Unknown) via an unspecified route of administration on an unknown date of Feb2021 (at the age of 82-year-old) at 13:30 as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within 4 weeks prior to the COVID-19 vaccine. On 01Mar2021, at 02:00, the patient experienced joint pain and chills. On 03Mar2021, two days later patient developed diarrhea. The patient did not receive any treatment for the reported events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events of joint pain, chills and diarrhea was recovered on an unknown date at the time of this report.   Information about lot number cannot be obtained. No further information is expected.
Age: 30.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site pain
Clinical narrative: Slight pain at vaccination site, not severe; This is a spontaneous report from a contactable consumer, the patient. A 30-years-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EP69SS) via an unspecified route of administration in left arm on 22Mar2021 at 13.00 (at the age of 30 years) as single dose, for COVID-19 immunisation. The patient had no medical history. The patient had not diagnosed with COVID-19 prior to vaccination. Patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient had no allergies to medications, food, or other products. Since the vaccination, the patient had not been tested positive for COVID-19. The patient did not receive any medication within 2 weeks of vaccination. On 22Mar2021 the patient experienced slight pain at vaccination site which was not severe. No treatment was received for the slight pain at vaccination site. The clinical outcome for the slight pain at vaccination site was recovering at the time of this report. No follow-up attempts are possible. No further information is expected.
Age: 37.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Irritability, Malaise, Myalgia, Pain in extremity
Clinical narrative: On days 2 and 3 general feeling of unwellness; Fatigue; Irritability; Arm was sore after 12 hours up until day 4; Just muscle pain; This is a spontaneous report from a contactable consumer, the patient. A 37-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER2613) via an unspecified route of administration in the left arm on 18Mar2021 at 12:45 as a single dose (at the age of 37-years-old) for COVID-19 immunisation. The patient medical history included asthma, allergies, ADHD. The patient also reported allergies to animals, molds, yeast, beef, and other food sensitivities. Concomitant medications reported as Advair (MANUFACTURER UNKNOWN), lamotrigine (MANUFACTURER UNKNOWN), buspar (MANUFACTURER UNKNOWN), atomoxetine (MANUFACTURER UNKNOWN) for an unknown indication on an unspecified date. The patient did not receive any other vaccine within four weeks prior to the COVID vaccine. Prior to vaccination, the patient was not tested positive for COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 19Mar2021 at 04:00, the patient experienced arm was sore after 12 hours up until day 4, just muscle pain. On days 2 and 3, general feeling of unwellness, fatigue, and irritability. The patient did not receive treatment for the reported events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the arm was sore, just muscle pain, general feeling of unwellness, fatigue and irritability was recovered at the time of the report.   No follow-up attempts are needed. No further information is expected.
Age: 60.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site erythema, Vaccination site pruritus
Clinical narrative: Large, red, itchy spot around injection site; Large, red, itchy spot around injection site; This is a spontaneous report from a contactable consumer, the patient. A 60-year-old non pregnant female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: EN6207), via an unspecified route of administration in the left arm on 12Mar2021 at 12:30 (at the age of 60-years-old) as a single dose for COVID-19 immunisation. The patient medical history was reported as stage 3B kidney disease/ pacemaker. The patient did not receive any other vaccines within 4 weeks prior to the COVID-19 vaccine. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. Concomitant medications included diltiazem (MANUFACTURER UNKNOWN), baby aspirin (MANUFACTURER UNKNOWN), multi-vitamin (MANUFACTURER UNKNOWN) and vitamin D (MANUFACTURER UNKNOWN), all taken for unknown indication and from an unknown date. On 18Mar2021, the patient experienced large, red, itchy spot around injection site that appeared about 1 week after vaccination. No therapeutic measures were taken as a result of the adverse events. The patient did not receive any treatment for the reported events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the event large, red, itchy spot around injection site was not resolved at the time of this report. No follow up attempts are needed. No further information is expected.
Age: 65.0
Sex: F
Vaccine: COVID19
Symptoms: Affect lability, Crying, Fatigue, Mood swings
Clinical narrative: Emotionally volatility; Constant weeping; Fatigue; Mood swings; This is a spontaneous report received from a contactable consumer, the patient. A 65-year-old non-pregnant female patient received unknown dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ENG206), via an unspecified route of administration in the right arm on 19Mar2021 at 13:00 (at the age of 65-years-old), as a single dose for COVID-19 immunisation. Medical history included haemophilia-C and thyroid cancer. Concomitant medications included SYNTHROID, metoprolol (MANUFACTURER UNKNOWN), lisinopril (MANUFACTURER UNKNOWN), progesterone (MANUFACTURER UNKNOWN); all for unknown indication from unknown date. The patient previously received VALIUM and LIBRIUM and experienced allergy. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient had not received any other vaccines within 4 weeks prior to the COVID-19 vaccine. On 19Mar2021 at 13:15, the patient experienced emotionally volatility, constant weeping, fatigue and mood swings. The adverse events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive treatment for the adverse events. The clinical outcome of the events emotionally volatility, constant weeping, fatigue and mood swings were not recovered at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 52.0
Sex: F
Vaccine: COVID19
Symptoms: Cough, Pain in extremity, Rhinorrhoea, Sneezing
Clinical narrative: Friday coughing; Sneezing runny nose; Sneezing runny nose; Pain at night in left arm; This is a spontaneous report from a contactable consumer, the patient. A 52-year-old non pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA vaccine; Lot number: EP6955), via an unspecified route of administration in the left arm on 18Mar2021 at 09:15 (at the age of 52-years-old), as a single dose for COVID-19 immunisation. The patient had no medical history. Concomitant medications were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient had no known allergies to medications, food, or other products. The patient experienced pain at night in the left arm on 18Mar2021 at 18:00. The following day, Friday, on 19Mar2021, the patient experienced coughing, sneezing and runny nose. The patient did not receive any treatment for the reported events. The clinical outcome of the events painful left arm, coughing, sneezing and runny nose was recovering at the time of this report.   No follow-up attempts are needed. No further information expected.
Age: 56.0
Sex: F
Vaccine: COVID19
Symptoms: Diarrhoea, Dry throat, Feeling hot, Flushing, Headache
Clinical narrative: This is a spontaneous report from a contactable consumer, the patient. A 56-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6207) via unspecified route of administration in the left arm on 17Mar2021 at 12:45 (at the age of 56-year-old), as a single dose for COVID-19 immunisation. The patients medical history included HFpEF heart Failure (heart failure with preserved ejection fraction), pulmonary hypertension, hypothydroidism, protein S deficiency, insulin resistant and high cholesterol. The patient was allergic to demerol, morphine, levaquin, ferahem E (IV iron), humira, penicillin and hydrocodone. The concomitant medications included ELIQUIS, BYSTOLIC, losartan (MANUFACTURER UNKNOWN), nifedipine (MANUFACTURER UNKNOWN) and much more of unspecified drugs which were taken since an unspecified date and unknown if ongoing. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient had not diagnosed with COVID-19. Since the vaccination, the patient had not tested positive for COVID-19. On 17Mar2021, the patient experienced the first sign of eyes feeling puffy within 21 minutes of the vaccination. On 17Mar202 at 13:15, the patient had very mild sporadic itching that began on the face and neck along with slight flushing/warmth. She also felt like throat was dry throat but wasn't thirsty. All of these symptoms were within an hour and half of the vaccine. The day after vaccine, the patient still had sporadic itching and dry throat. Two days after the vaccination, the patient had a light headache that lasted for 2 days and had a onetime episode of diarrhoea with slight nausea on an unspecified date in Mar2021. Thereafter everything was good. The patient had taken Benadryl as a therapeutic measure. The events didn't result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events of eyes feeling puffy, very mild sporadic itching on face and neck, slight flushing/warmth, dry throat, onetime episode of diarrhoea with slight nausea was recovered on an unspecified date in Mar2021 and the clinical outcome of light headache was recovered on 22Mar2021. No follow-up attempts are needed. No further information was expected.
Age: 56.0
Sex: F
Vaccine: COVID19
Symptoms: Nausea, Periorbital swelling, Pruritus
Clinical narrative: This is a spontaneous report from a contactable consumer, the patient. A 56-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6207) via unspecified route of administration in the left arm on 17Mar2021 at 12:45 (at the age of 56-year-old), as a single dose for COVID-19 immunisation. The patients medical history included HFpEF heart Failure (heart failure with preserved ejection fraction), pulmonary hypertension, hypothydroidism, protein S deficiency, insulin resistant and high cholesterol. The patient was allergic to demerol, morphine, levaquin, ferahem E (IV iron), humira, penicillin and hydrocodone. The concomitant medications included ELIQUIS, BYSTOLIC, losartan (MANUFACTURER UNKNOWN), nifedipine (MANUFACTURER UNKNOWN) and much more of unspecified drugs which were taken since an unspecified date and unknown if ongoing. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient had not diagnosed with COVID-19. Since the vaccination, the patient had not tested positive for COVID-19. On 17Mar2021, the patient experienced the first sign of eyes feeling puffy within 21 minutes of the vaccination. On 17Mar202 at 13:15, the patient had very mild sporadic itching that began on the face and neck along with slight flushing/warmth. She also felt like throat was dry throat but wasn't thirsty. All of these symptoms were within an hour and half of the vaccine. The day after vaccine, the patient still had sporadic itching and dry throat. Two days after the vaccination, the patient had a light headache that lasted for 2 days and had a onetime episode of diarrhoea with slight nausea on an unspecified date in Mar2021. Thereafter everything was good. The patient had taken Benadryl as a therapeutic measure. The events didn't result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events of eyes feeling puffy, very mild sporadic itching on face and neck, slight flushing/warmth, dry throat, onetime episode of diarrhoea with slight nausea was recovered on an unspecified date in Mar2021 and the clinical outcome of light headache was recovered on 22Mar2021. No follow-up attempts are needed. No further information was expected.
Age: 36.0
Sex: M
Vaccine: COVID19
Symptoms: Pain in extremity
Clinical narrative: Sore arm; This is a spontaneous report from a contactable consumer, the patient. A 36-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN), via an unspecified route of administration in the left arm on 22Mar2021 at 1500 (at the age of 36-years-old), as a single dose for COVID-19 immunisation. Medical history was not reported. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Concomitant medication was not reported. On 22Mar2021 1500, the patient experienced sore arm. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive treatment for the events. The clinical outcome for the event sore arm was resolving at the time of the report.   Information about lot/batch number cannot be obtained. No further information is expected.
Age: 34.0
Sex: F
Vaccine: COVID19
Symptoms: Epistaxis
Clinical narrative: experienced profuse nose bleeding from right nostril; This is a spontaneous report from a contactable consumer, the patient. A 34-year-old non-pregnant female patient received her second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, lot number: EN6208), via an unspecified route of administration in the left arm on 20Mar2021 at 13:30 as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. The patient had previously received her first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, lot number: EN6198), via an unspecified route of administration in the left arm on 27Feb2021 at 15:30 as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient was not diagnosed with COVID-19 prior to vaccination. On 22Mar2021 at 16:45, the patient experienced profuse nose bleeding from right nostril and no treatment was received for this event. On 17Mar2021, 10Mar2021 and 03Mar2021, the patient underwent nasal swab test for COVID-19 and the result was negative for all the three times. The clinical outcome of the event profuse nose bleeding was resolved.   No follow-up attempts are needed. No further information is expected.
Age: 33.0
Sex: F
Vaccine: COVID19
Symptoms: Pruritus, Rash
Clinical narrative: Extremely itchy; light rash down the arm; This is a spontaneous report from a contactable consumer, the patient. A 33-years-old non-pregnant female patient received first dose of BNT162B2 (PFIZER BIONTECH COVID-19 mRNA VACCINE; Lot number: tn6208) via an unspecified route of administration in right arm on 09Mar2021 at 18:00 (at the age of 33-years) as a single dose for COVID-19 Immunisation. Medical history included inflammatory arthritis. The patient was allergic to penicillin, sulfa, Vicodin and zofran. Concomitant medications were not reported. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID-19 vaccine. On 09Mar2021, a few hours after vaccination, the patient experienced a light rash down the arm in which she got her shot in as well. When the patient woke up the next day, the rash on her arm had faded but her hand was worse and it was extremely itchy. Now, it was all over her neck and it was extremely itchy. The patient still had the rash and it had been 13 days. It was not responding to Benadryl anti-itch cream. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the event rash was resolving whereas itchy was not resolved at the time of report.   No follow-up attempts are needed. No further information is expected.
Age: 26.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Chills, Dysphagia, Headache, Heart rate increased
Clinical narrative: joint pain; arm pain; swollen lymph nodes; chills; headache; rapid heart beat; trouble swallowing; This is a spontaneous report from a contactable consumer, the patient. A 26-years-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6207) via an unspecified route of administration in left arm on 17Mar2021 at 08:30 (at the age of 26-years-old) as a single dose for COVID-19 immunisation. Medical history included asthma and penicillin allergy. Concomitant medications included daily vitamins (unspecified) and unspecified allergy medicines. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 17Mar2021 at 09:00, the patient experienced joint pain, arm pain, swollen lymph nodes, chills, headache, rapid heartbeat, and trouble swallowing for a short period of time. No therapeutic measures were taken for the events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events joint pain, arm pain, swollen lymph nodes, chills, headache, heartbeat increased and trouble swallowing was recovered on an unknown date in Mar2021.   No follow-up attempts are needed. No further information is expected.
Age: 26.0
Sex: F
Vaccine: COVID19
Symptoms: Lymphadenopathy, Pain in extremity
Clinical narrative: joint pain; arm pain; swollen lymph nodes; chills; headache; rapid heart beat; trouble swallowing; This is a spontaneous report from a contactable consumer, the patient. A 26-years-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6207) via an unspecified route of administration in left arm on 17Mar2021 at 08:30 (at the age of 26-years-old) as a single dose for COVID-19 immunisation. Medical history included asthma and penicillin allergy. Concomitant medications included daily vitamins (unspecified) and unspecified allergy medicines. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 17Mar2021 at 09:00, the patient experienced joint pain, arm pain, swollen lymph nodes, chills, headache, rapid heartbeat, and trouble swallowing for a short period of time. No therapeutic measures were taken for the events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events joint pain, arm pain, swollen lymph nodes, chills, headache, heartbeat increased and trouble swallowing was recovered on an unknown date in Mar2021.   No follow-up attempts are needed. No further information is expected.
Age: 47.0
Sex: F
Vaccine: COVID19
Symptoms: Rash
Clinical narrative: Rash on both legs from mid thigh to ankle and inside wrist and left arm.; This is a spontaneous report from a contactable consumer, the patient. A 47-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: unknown) via an unspecified route of administration in the left arm on 16Mar2021 at 12:00 (at the age of 47-years-old) as a single dose for COVID-19 immunisation. The patient had a history of allergy to pineapples. The concomitant medications were not reported. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient was not tested for COVID-19. On 19Mar2021 at 19:00, the patient experienced rash on both legs from mid-thigh to ankle and inside wrist and left arm (rash). It lasted for 3 days, but did not start until 19Mar2021, 3 days after vaccination. The second dose was scheduled on 06Apr2021. No therapeutic measures were taken for the reported event. The events had not resulted in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care visit. The clinical outcome of the event rash was resolved on 22Mar2021.   Information about lot/batch number cannot be obtained. No further information is expected.
Age: 49.0
Sex: F
Vaccine: COVID19
Symptoms: Pruritus, Rash, Rash pruritic
Clinical narrative: Itchy painful rash that began on left wrist and hand. Within 12 hours, it spread across my torso, up my chest and on to my other wrist/hand; Small bumps similar in appearance to heat rash, they itch terribly and sometimes felt bruised; Itchy painful rash that began on left wrist and hand. Within 12 hours, it spread across my torso, up my chest and on to my other wrist/hand; Small bumps similar in appearance to heat rash, they itch terribly and sometimes felt bruised; This is a spontaneous report from a contactable consumer, the patient. A 49-year-old non-pregnant female patient received her first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6200) via unspecified route of administration in left arm, on 08Mar2021 at 15:00 (at the age of 49-year-old) as a single dose for COVID-19 immunisation. Past medical history included allergies to penicillin, cephalosporins and nickel. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested positive for COVID-19. Medications were used within 2 weeks of vaccination included levothyroxine (MANUFACTURER UNKNOWN), fludrocortisone (MANUFACTURER UNKNOWN), effexor (MANUFACTURER UNKNOWN) and loestrin (MANUFACTURER UNKNOWN), for an unknown indication. The facility where the most recent COVID-19 vaccine was administered was at a hospital. On 17Mar2021 at 05:45, the patient experienced an itchy painful rash that began on her left wrist and hand. Within 12 hours, it spread across torso, up chest and on to other wrist/hand. Small bumps similar in appearance to heat rash. They itch terribly, and sometimes it feels bruised. Therapeutic measures had taken as resulted to events and included the treatment with steroids and benedryl orally. It was reported that, the patient had slept for a few days because of that and had the rash for 5 days and didn't feel it getting better. The adverse events didn't result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome for events itchy rash, painful rash, itchy and bruised was not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected.
Sex: F
Vaccine: COVID19
Symptoms: Fatigue
Clinical narrative: felt tired; This is a spontaneous report from a contactable consumer. An adult non-pregnant female patient of an unspecified age received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: unknown), via an unspecified route of administration on 18Mar2021 as a single dose for COVID-19 immunisation. Medical history was not reported. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: unknown), via an unspecified route of administration on an unspecified date as a single dose for COVID-19 immunisation. It was unknown if the patient had received any medication within two weeks of the COVID-19 vaccine. It was unknown if the patient had received any other vaccines within 4 weeks prior to the COVID-19 vaccine. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, it was unknown if the patient had tested positive for COVID-19. On an unspecified date in Mar2021, the patient felt tired the weekend after receiving the second dose. It was unknown if any therapeutic measures were taken for the event felt tired. The adverse event did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the event felt tired was unknown. Information about lot/ batch number cannot be obtained. No further information is expected.